Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis

Table 3

Univariate meta-regression analyses for the association between patient and treatment characteristics with the efficacy outcomes.

	RR for sputum culture conversion to negative
Covariate	Coefficient	95% CI
No. of patients	0.047	−0.148 to 0.242	0.67
Mean age (years)	−0.032	−0.099 to 0.035	0.59
rhuIL-2 dose (10^4 IU/d)	0.0027	−0.0011 to 0.0065	0.18
rhuIL-2 routes	−0.06	−0.17 to 0.05	0.29
Treatment duration (months)	0.18	−0.22 to 0.58	0.49
	RR for sputum smear conversion to negative
Covariate	Coefficient	95% CI
No. of patients	0.19	−0.04 to 0.42	0.11
Mean age (years)	0.009	−0.017 to 0.035	0.63
rhuIL-2 dose (10^4 U/d)	−0.013	−0.251 to 0.225	0.92
rhuIL-2 routes	−0.31	−0.97 to 0.35	0.36
Treatment duration (months)	0.33	−0.10 to 0.76	0.18
	RR for radiographic focus absorption
Covariate	Coefficient	95% CI
No. of patients	0.03	−0.19 to 0.25	0.85
Mean age (years)	−0.044	−0.102 to 0.014	0.13
rhuIL-2 dose (10^4 IU/d)	−0.052	−0.153 to 0.049	0.36
rhuIL-2 routes	−0.063	−0.272 to 0.146	0.64
Treatment duration (months)	0.14	−0.58 to 0.86	0.77
	RR for radiographic cavity closure
Covariate	Coefficient	95% CI
No. of patients	−0.012	−0.511 to 0.487	0.93
Mean age (years)	0.091	−0.072 to 0.254	0.10
rhuIL-2 dose (10^4 IU/d)	0.058	−0.122 to 0.238	0.52
rhuIL-2 routes	−0.015	−0.523 to 0.493	0.96
Treatment duration (months)	−0.072	−0.301 to 0.157	0.61

rhuIL-2, recombinant human interleukin-2; RR, risk ratio; CI, confidence interval.